论文部分内容阅读
目的:针对急性严重的呼吸道感染患者进行头孢曲松钠药物干预治疗,记录治疗过程观察临床干预治疗效果,并进行分析。方法:在该院选取120例急性严重呼吸道感染疾病患者资料以上患者资料收集时间从2014年2月至2015年11月。根据患者病症对患者资料进行随机分组,其中,接受头孢曲松钠治疗的患者,即为头孢曲松钠治疗组;另外接受常规急性严重呼吸道感染治疗的患者,即为常规治疗组。结果:头孢曲松钠治疗组患者治疗的总有效为96.6%,常规治疗组治疗的总有效率为75%,结果显示头孢曲松钠组治疗的效果明显优于常规治疗组的效果,两者比较存在差异(P<0.05),比较具有统计学意义。结论:针对急性严重的呼吸道感染患者采取头孢曲松钠药物进行干预治疗有明显的疗效,能够减轻患者病症,为患者提升生活质量,具有着重要的应用价值,值得在临床治疗中推广。
OBJECTIVE: To ceftriaxone sodium intervention in patients with acute and severe respiratory infections, and to observe the effect of clinical intervention in the course of treatment, and to analyze. Methods: The data of 120 patients with acute severe respiratory infection were selected in this hospital from February 2014 to November 2015. Patient data were randomly assigned according to the patient’s condition. Among them, patients receiving ceftriaxone sodium were treated with ceftriaxone sodium; patients receiving conventional acute severe respiratory infection were also treated as conventional treatment. Results: The total effective rate of ceftriaxone treatment group was 96.6%, while the total effective rate of routine treatment group was 75%. The results showed that the effect of ceftriaxone sodium group was better than that of conventional treatment group, both There are differences (P <0.05), more statistically significant. Conclusion: It is of great value to improve the quality of life of patients with acute respiratory infections by taking ceftriaxone sodium for intervention. It is worth to be promoted in clinical treatment.